Molecular alterations and emerging targets in castration resistant prostate cancer

European Journal of Cancer

Volumn 50, Issue 4, 2014, Pages 753-764

  Lorente, D ^a   De Bono, J S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Androgen receptor; Castration resistant prostate cancer; Molecular biology; Novel therapeutics

Indexed keywords

ANDROGEN RECEPTOR; CASTRATION RESISTANT PROSTATE CANCER; MOLECULAR BIOLOGY; NOVEL THERAPEUTICS;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT FAILURE;

EID: 84894059406     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.12.004     Document Type: Review

References (129)

1. Prostate cancer incidence statistics. Cancer Res. UK, pp. 1-8; 2013.
2. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995;346:265-9.
3. I.F. Tannock, R. de Wit, and W.R. Berry et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 15 2004 1502 1512
4. J.S. De Bono, S. Oudard, and M. Ozguroglu et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 9747 2010 1147 1154
5. J.S. De Bono, C.J. Logothetis, and A. Molina et al. Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 21 2011 1995 2005
6. H.I. Scher, K. Fizazi, and F. Saad et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 13 2012 1187 1197
7. P. Kantoff, C. Higano, and N. Shore et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 5 2010 411 422
8. C. Parker, S. Nilsson, and D. Heinrich et al. Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 3 2013 213 223
9. C.J. Ryan, M.R. Smith, and J.S. de Bono et al. Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2 2013 138 148
10. C. Jerónimo, P.J. Bastian, and A. Bjartell et al. Epigenetics in prostate cancer: biologic and clinical relevance Eur Urol 60 4 2011 753 766
11. E. Cha, and L. Fong Immunotherapy for prostate cancer: biology and therapeutic approaches J Clin Oncol 29 27 2011 3677 3685
12. W.R. Gerritsen The evolving role of immunotherapy in prostate cancer Ann Oncol 23 Suppl. 8 2012 viii22 viii27
13. M.M. Shen, and C. Abate-Shen Molecular genetics of prostate cancer: new prospects for old challenges Genes Dev 24 18 2010 1967 2000
14. B.S. Taylor, N. Schultz, and H. Hieronymus et al. Integrative genomic profiling of human prostate cancer Cancer Cell 18 1 2010 11 22
15. C. Grasso, Y. Wu, and D. Robinson The mutational landscape of lethal castration-resistant prostate cancer Nature 487 7406 2012 239 243
16. C.E. Barbieri, S.C. Baca, and M.S. Lawrence et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer Nat Genet 44 6 2012 685 689
17. C. Bowen, and E.P. Gelmann NKX3.1 activates cellular response to DNA damage Cancer Res 70 8 2010 3089 3097
18. H. Chen, A.K. Nandi, and X. Li NKX-3.1 interacts with prostate-derived ETS factor and regulates the activity of the PSA promoter Cancer Res 62 2 2002 338 340
19. D. Bernard, and A. Pourtier-Manzanedo Myc confers androgen-independent prostate cancer cell growth J Clin Invest 112 11 2003 1724 1731
20. L. Gao, J. Schwartzman, and A. Gibbs et al. Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation PLoS One 8 5 2013 e63563
21. J.E. Delmore, G.C. Issa, and M.E. Lemieux et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc Cell 146 6 2011 904 917
22. A.V. D'Amico, S. Halabi, and R. Vollmer et al. P53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682) Urology 71 5 2008 933 937
23. C. Liu, Y. Zhu, and W. Lou et al. Functional p53 determines docetaxel sensitivity in prostate cancer cells Prostate 73 4 2013 418 427
24. K. Macleod, and R.B. The Tumor suppressor: a gatekeeper to hormone independence in prostate cancer? J Clin Invest 120 12 2010 4179 4182
25. A. Aparicio, R.B. Den, and K.E. Knudsen Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer Nat Rev Urol 8 10 2011 562 568
26. S. Huang, Z.G. Gulzar, and K. Salari et al. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness Oncogene 31 37 2012 4164 4170
27. W. Liu, J. Lindberg, and G. Sui et al. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer Oncogene 31 35 2012 3939 3948
28. G. Petrovics, A. Liu, and S. Shaheduzzaman et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome Oncogene 24 23 2005 3847 3852
29. G. Attard, J.F. Swennenhuis, and D. Olmos et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 7 2009 2912 2918
30. S.A. Tomlins, D.R. Rhodes, and S. Perner et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 310 5748 2005 644 648
31. S.A. Tomlins, B. Laxman, and S.M. Dhanasekaran et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer Nature 448 7153 2007 595 599
32. A. Paju, and U.-H. Stenman Biochemistry and clinical role of trypsinogens and pancreatic secretory trypsin inhibitor Crit Rev Clin Lab Sci 43 2 2006 103 142
33. S.A. Tomlins, D.R. Rhodes, and J. Yu et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers Cancer Cell 13 6 2008 519 528
34. B. Ateeq, S.A. Tomlins, and B. Laxman et al. Therapeutic targeting of SPINK1-positive prostate cancer Sci Transl Med 3 72 2011 72ra17
35. H. Beltran, D.S. Rickman, and K. Park et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets Cancer Discov 1 6 2011 487 495
36. H.J. Meulenbeld, J.P. Bleuse, and E.M. Vinci et al. Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure BJU Int 111 1 2013 44 52
37. G. Brooke, and C. Bevan The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 2009;10(1):18-25 9 2009 18 25
38. M.A. Augello, T.E. Hickey, and K.E. Knudsen FOXA1: master of steroid receptor function in cancer EMBO J 30 19 2011 3885 3894
39. B. Sahu, M. Laakso, and P. Pihlajamaa et al. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells Cancer Res 73 5 2012 1570 1580
40. M. Kawase, T. Toyama, and S. Takahashi et al. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer Breast cancer 2013 1 9
41. H.-J. Jin, J.C. Zhao, and I. Ogden et al. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis Cancer Res 73 12 2013 3725 3736
42. I.U. Agoulnik, A. Vaid, and W.E. Bingman et al. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression Cancer Res 65 17 2005 7959 7967
43. J. Yan, H. Erdem, and R. Li et al. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression Cancer Res 68 13 2008 5460 5468
44. J. Yan, C.-T. Yu, and M. Ozen et al. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway Cancer Res 66 22 2006 11039 11046
45. M.F. Berger, M.S. Lawrence, and F. Demichelis et al. The genomic complexity of primary human prostate cancer Nature 470 7333 2011 214 220
46. C. Geng, B. He, and L. Xu et al. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover Proc Natl Acad Sci U S A 110 17 2013 6997 7002
47. J. Tien, and J. Xu Steroid receptor coactivator-3 as a potential molecular target expert for cancer therapy Expert Opin Ther Targets 16 11 2012 1085 1096
48. C. Tran, S. Ouk, and N. Clegg et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 5928 2009 787 790
49. D.B. Agus, and W.M. Stadler Safety, efficacy and pharmacodynamics of orteronel (TAK-700) in metastatic castration resistant prostate cancer: Updated data from a phase I/II study ASCO Meet Abstr 30 Suppl. 5; abstr. 98 2012 7 9
50. D. Petrylak, J.G. Gandhi, and W.R. Clark et al. A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results ASCO Meet Abstr 31 Suppl. 6 2013 59
51. J.R. Eisner, D.H. Abbott, and I.M. Bird et al. VT-464: A novel, selective inhibitor of P450c17(CYP17)-17,20 lyase for castration-refractory prostate cancer (CRPC) ASCO Meet Abstr 30 Suppl. 15 2012 e15167
52. N.J. Clegg, J. Wongvipat, and J.D. Joseph et al. ARN-509: a novel antiandrogen for prostate cancer treatment Cancer Res 72 6 2012 1494 1503
53. D.E. Rathkopf, E.S. Antonarakis, and N.D. Shore et al. ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC) ASCO Meet Abstr 31 Suppl. 6 2013 48
54. Taplin M-E, Chu F. ARMOR1: Safety of galeterone (TOK-001) in a Phase I clinical trial in chemotherapy naïve patients with castration resistant prostate cancer. Cancer Res 2012;72(Suppl 8):CT-07.
55. M.N. Stein, S. Goodin, and R.S. Dipaola Abiraterone in prostate cancer: a new angle to an old problem Clin Cancer Res 18 7 2012 1848 1854
56. S.M. Dehm, L.J. Schmidt, and H.V. Heemers et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance Cancer Res 68 13 2008 5464 5477
57. E.A. Mostaghel, B.T. Marck, and S.R. Plymate et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants Clin Cancer Res 17 18 2011 5913 5925
58. R. Hu, C. Lu, and E.A. Mostaghel et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer Cancer Res 72 14 2012 3457 3462
59. X.Y. Zhao, P.J. Malloy, and V. Krishnana et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor Nat Med 6 6 2000 703 706
60. J. Richards, A.C. Lim, and C.W. Hay et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100 Cancer Res 72 9 2012 2176 2182
61. G. Attard, A.H.M. Reid, and T.A. Yap et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven J Clin Oncol 26 28 2008 4563 4571
62. C. Cai, S. Chen, and P. Ng et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors Cancer Res 71 20 2011 6503 6513
63. T.A. Yap, A. Zivi, and A. Omlin et al. The changing therapeutic landscape of castration-resistant prostate cancer Nat Rev Clin Oncol 8 10 2011 597 610
64. M.V. Powers, and P. Workman Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors Endocr Relat Cancer 13 Suppl. 1 2006 S125 S135
65. J. Trepel, M. Mollapour, G. Giaccone, and L. Neckers et al. Targeting the dynamic HSP90 complex in cancer Nat Rev Cancer 10 8 2010 537 549
66. U. Banerji Heat shock protein 90 as a drug target: some like it hot Clin Cancer Res 15 1 2009 9 14
67. A.J. Saporita, J. Ai, and Z. Wang The Hsp90 Inhibitor, 17-AAG, Prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells Prostate 67 5 2007 509 520
68. D.K. Vanaja, S.H. Mitchell, and D.O. Toft et al. Effect of geldanamycin on androgen receptor function and stability Cell Stress Chaperones 7 1 2002 55 64
69. A. Yano, S. Tsutsumi, and S. Soga et al. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone Proc Natl Acad Sci 105 23 2008 15541 15546
70. F. Lamoureux, C. Thomas, and M.-J. Yin et al. A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis Clin Cancer Res 17 8 2011 2301 2313
71. E. Voll, I. Ogden, and X. Huang et al. Abstract 5331: the effect of heat shock protein 27 (HSP27) on prostate cancer cell adhesion, invasion and metastasis Cancer Res 72 Suppl. 8 2012 5331
72. P. Rocchi, A. So, and S. Kojima et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer Cancer Res 64 2004 6595 6602
73. K.N. Chi, S.J. Hotte, and S. Ellard et al. A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer ASCO Meet Abstr 30 Suppl. 5 2012 121
74. A. Zoubeidi, K. Chi, and M. Gleave Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer Clin Cancer Res 16 4 2010 1088 1093
75. I.P. Trougakos, M. Lourda, and M.H. Antonelou et al. Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex Clin Cancer Res 15 1 2009 48 59
76. H. Miyake, C. Nelson, and P.S. Rennie et al. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models Cancer Res 60 9 2000 2547 2554
77. L.V. July, M. Akbari, and T. Zellweger et al. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002;50(3):179-188 50 2002 179 188
78. K.N. Chi, E. Eisenhauer, and L. Fazli et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer J Natl Cancer Inst 97 17 2005 1287 1296
79. K.N. Chi, S.J. Hotte, and E.Y. Yu et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer J Clin Oncol 28 27 2010 4247 4254
80. N. McCabe, N.C. Turner, and C.J. Lord et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition Cancer Res 66 16 2006 8109 8115
81. P. Fong, D. Boss, and T. Yap et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2 2009 123 134
82. J.C. Brenner, B. Ateeq, and Y. Li et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer Cancer Cell 19 5 2011 664 678
83. C. Lin, L. Yang, and B. Tanasa et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer Cell 139 6 2009 1069 1083
84. M. Schiewer, J. Goodwin, and S. Han Dual roles of PARP-1 promote cancer growth and progression Cancer Discov 2 12 2012 1134 1149
85. J.C. Barreto-Andrade, E.V. Efimova, and H.J. Mauceri et al. Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation Mol Cancer Ther 10 7 2011 1185 1193
86. P. Chatterjee, G.S. Choudhary, and A. Sharma et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells PLoS One 8 4 2013 e60408
87. D. Sarker, A.H.M. Reid, and T.A. Yap et al. Targeting the PI3K/AKT pathway for the treatment of prostate cancer Clin Cancer Res 15 15 2009 4799 4805
88. B. Carver, J. Tran, and A. Gopalan et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate Nat Genet 41 5 2009 619 624
89. D.J. Mulholland, S. Dedhar, and H. Wu et al. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer Oncogene 25 3 2006 329 337
90. S. Wang, J. Gao, and Q. Lei et al. Prostate-specific deletion of the murine PTEN tumor suppressor gene leads to metastatic prostate cancer Cancer Cell 4 3 2003 209 221
91. R.J. Amato, G. Wilding, and G. Bubley et al. Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients prostate cancer Clin Genitourin Cancer 10 4 2012 232 238
92. K. Kruczek, M. Ratterman, and K. Tolzien et al. A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer Br J Cancer 109 7 2013 1711 1716
93. A.J. Armstrong, T. Shen, and S. Halabi et al. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer Clin Genitourin Cancer 11 4 2013 397 406
94. A.J. Templeton, V. Dutoit, and R. Cathomas et al. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08) Eur Urol 64 1 2013 150 158
95. B.S. Carver, C. Chapinski, and J. Wongvipat et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer Cancer Cell 19 5 2011 575 586
96. R.P. Funke, J. Zhu, and R.D. Meng et al. A phase Ib/II study testing the safety and efficacy of combined inhibition of the AKT/PI3K and AR signaling pathways in castration-resistant prostate cancer: GDC-0068 or GDC-0980 with abiraterone acetate versus abiraterone acetate ASCO Meet Abstr 30 Suppl. 15 2012 TPS2616
97. J. Riedemann, and V.M. Macaulay IGF1R signalling and its inhibition Endocr Relat Cancer 13 Suppl. 1 2006 S33 S43
98. M.-A. Rowlands, J.M.P. Holly, and D. Gunnell et al. Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT Cancer Res 72 2 2012 503 515
99. K.N. Chi, M.E. Gleave, and L. Fazli et al. A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer Clin Cancer Res 18 12 2012 3407 3413
100. C.D. Fahrenholtz, P.J. Beltran, and K.L. Burnstein Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts Mol Cancer Ther 12 4 2013 394 404
101. F. Dayyani, N.U. Parikh, and A.S. Varkaris et al. Combined inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways PLoS One 7 12 2012 e51189
102. G.R. Blumenschein, G.B. Mills, and A.M. Gonzalez-Angulo Targeting the hepatocyte growth factor-cMET axis in cancer therapy J Clin Oncol 30 26 2012 3287 3296
103. P. Michieli, C. Basilico, and S. Pennacchietti Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists Oncogene 18 37 1999 5221 5231
104. C. Boccaccio, and P. Comoglio Invasive growth: a MET-driven genetic programme for cancer and stem cells Nat Rev Cancer 6 8 2006 637 645
105. B.S. Knudsen, G.A. Gmyrek, and J. Inra et al. High expression of the Met receptor in prostate cancer metastasis to bone Urology 60 6 2002 1113 1117
106. M. Verras, J. Lee, and H. Xue et al. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression Cancer Res 67 3 2007 967 975
107. F.M. Yakes, J. Chen, and J. Tan et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth Mol Cancer Ther 10 12 2011 2298 2308
108. P. Schoffski, R. Elisei, and S. Muller et al. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline ASCO Meet Abstr 30 Suppl. 15 2012 5508
109. D.C. Smith, M.R. Smith, and C. Sweeney et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial J Clin Oncol 31 4 2013 412 419
110. M.R. Smith, C. Sweeney, and D.E. Rathkopf et al. Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): results from a phase II nonrandomized expansion cohort (NRE) ASCO Meet Abstr 30 Suppl. 15 2012 4513
111. J.S. De Bono, S. Rathkopf, and D. Corn Cabozantinib (XL184) at 40 mg in patients with metastatic castration resistant prostate cancer (mCRPC): results from a phase 2 non-randomized expansion cohort (NRE) Ann Oncol 23 Suppl. 1 2012 8970
112. J. Picus, S. Halabi, and W.K. Kelly et al. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006 Cancer 117 3 2011 526 533
113. W.K. Kelly, S. Halabi, and M. Carducci et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401 J Clin Oncol 30 13 2012 1534 1540
114. I. Tannock, K. Fizazi, and S. Ivanov et al. Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): results from the multinational phase III trial (VENICE) ASCO Meet Abstr 31 Suppl. 6 2013 13
115. Celgene. Press release - celgene will discontinue phase III MAINSAIL(R) trial in castrate resistant prostate cancer. Available from: http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID= 1633148&highlight=.
116. B. Adesunloye, X. Huang, and Y.M. Ning et al. Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) ASCO Meet Abstr 30 Suppl. 15 2012 4569
117. R. Pili, M. Häggman, and W.M. Stadler et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer J Clin Oncol 29 30 2011 4022 4028
118. A.J. Armstrong, M. Haggman, and W.M. Stadler et al. Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial ASCO Meet Abstr 30 Suppl. 15 2012 4550
119. M.A. Carducci Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial J Clin Oncol 21 4 2003 679 689
120. N.D. James, A. Caty, and H. Payne et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind BJU Int 106 7 2010 966 973
121. J.B. Nelson, W. Love, and J.L. Chin et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer Cancer 113 9 2008 2478 2487
122. J.B. Nelson, K. Fizazi, and K. Miller et al. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone Cancer 118 22 2012 5709 5718
123. D.I. Quinn, C.M. Tangen, and M. Hussain et al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial Lancet Oncol 14 9 2013 893 900
124. K.S. Fizazi, C.S. Higano, and J.B. Nelson et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer J Clin Oncol 31 14 2013 1740 1747
125. F. Saad, and A. Lipton SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer Cancer Treat Rev 36 2 2010 177 184
126. H. Cai, I. Babic, and X. Wei et al. Invasive prostate carcinoma driven by c-Src and androgen receptor synergy Cancer Res 71 3 2011 862 872
127. E.Y. Yu, G. Wilding, and E. Posadas et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer Clin Cancer Res 15 23 2009 7421 7428
128. J. Araujo, A.J. Armstrong, and E.L. Braud et al. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: a phase I/II study (CA180086) ASCO Meet Abstr 27 Suppl. 15 2009 5061
129. J.C. Araujo, G.C. Trudel, and F. Saad et al. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): results from the randomized phase III READY trial ASCO Meet Abstr 31 Suppl. 6 2013 LBA8